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A b s t r a c t
The spatial patterns of the diffuse, primitive, and classic β-amyloid (Aβ) deposits were compared in cortical regions
in early-onset familial Alzheimer’s disease (EO-FAD) linked to mutations of the amyloid precursor protein APP) or
presenilin 1 (PSEN1) genes, late-onset familial AD (LO-FAD), and sporadic AD (SAD). The objective was to determine
whether genetic factors influenced the spatial patterns of the Aβ deposits. Aβ deposits were distributed either in
clusters which were regularly distributed parallel to the pia mater or in larger, non-regularly distributed clusters.
There were no significant differences in spatial pattern of the diffuse deposits between patient groups but mean
cluster size of the diffuse deposits was larger in FAD compared with SAD. Primitive Aβ deposits were more frequently
distributed in regular clusters and less frequently distributed in large clusters in FAD compared with SAD. Classic Aβ
deposits were more frequently distributed in regularly spaced clusters and less frequently distributed in large clus-
ters in LO-FAD compared with EO-FAD. There were no significant differences in the spatial patterns or cluster sizes
of Aβ deposits in cases classified according to apolipoprotein E (APOE) genotype. These results suggest (1) greater
deposition of Aβ in the form of clusters of diffuse deposits in FAD, (2) a greater proportion of diffuse deposits may
be converted to primitive deposits in SAD, (3) classic deposits are more widely distributed in EO-FAD, and (4) the
presence of APOE allele ε4 has little effect on the spatial patterns of Aβ deposits.
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The neuropathology of Alzheimer’s disease (AD)
is characterised by the formation of extracellular se -
nile plaques (SP) and intracellular neurofibrillary tan-
gles (NFT) [8]. The most important molecular consti -
tuent of the SP is β-amyloid (Aβ) [27], a peptide of
36-43 amino acids arising by constitutive cleavage of
a trans-membrane glycoprotein amyloid precursor
pro tein (APP). A variety of Aβ peptides are formed as
a result of secretase cleavage of APP [31]. The most
common of these peptides is Aβ42, cleaved in the
trans-Golgi network and found largely in discrete Aβ
deposits, whereas the more soluble Aβ40, cleaved in
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the endoplasmic reticulum, is also found in associa-
tion with blood vessels [41,45] and may develop lat-
er in the disease [23]. Oligomers that form on the
amyloid pathways may be cytotoxic species rather
than Aβ42 [37]. The discovery of β-amyloid (Aβ) led to
the formulation of the ‘amyloid cascade hypothesis’
(ACH), the most important model of the molecular
pathology of AD developed over the last 20 years
[32]. Essentially, the ACH proposes that the deposi-
tion of Aβ is the initial pathological event in AD lead-
ing to the formation of NFT, cell death, and ultima -
tely dementia. 
At least four genetic loci have been implicated in
AD, viz., the APP gene on chromosome 21 [20,28],
the presenilin (PSEN) genes on chromosomes 14
(PSEN1) [48] and 1 (PSEN2) [38], and the apolipopro-
tein E (APOE) gene on chromosome 19 [47]. Muta-
tions in APP and PSEN genes may alter APP meta b-
olism, resulting in increased deposition of Aβ, while
allelic polymorphism of APOE, and especially the
expression of the ε4 allele, may increase the propor-
tion of the more fibrillogenic Aβ42 formed in the tis-
sue [18,19,25]. These genetic factors, however, may
not explain the majority of AD cases [30]. Hence,
early-onset AD linked to APP and PSEN mutations
may account for less than 5% of the total number of
cases [34]. Additional susceptibility genes and envi-
ronmental factors are therefore likely to be involved
in AD, especially in sporadic cases. In isolated Amish
communities, for example, 24 markers have been
linked to dementia [40], and several other linkage
studies have shown the presence of possible AD-
related genes on chromosomes 9, 10, and 12 [49]. 
Three morphological subtypes of Aβ deposit are
observed in histological preparations of AD brain
[5,22]: (1) diffuse (‘pre-amyloid’) deposits, in which
the Aβ peptide is not aggregated into amyloid and
dystrophic neuritis (DN) and paired helical filaments
(PHF) are infrequent or absent, (2) primitive (‘neuri -
tic’) deposits, in which the Aβ is aggregated into 
amyloid and is associated with DN and PHF, and 
(3) classic (‘cored’) deposits, in which Aβ is highly
aggregated to form a central amyloid ‘core’ sur-
rounded by a ‘ring’ of DN. Diffuse Aβ deposits are
often spatially correlated with neuronal perikarya
[1,6] and may represent the earliest stages of Aβ
deposition in AD [5]. Different Aβ deposit subtypes
could represent stages in the maturation of a single
deposit type [5]. Hence, diffuse deposits may evolve
into more mature deposits as the disease progres -
ses [5].
Aβ deposits are often clustered in the cerebral
cortex, the clusters being distributed in a regular
pattern parallel to the pia mater [13,15,17], and may
be the result of Aβ pathology developing in relation
to the cortico-cortical and cortico-hippocampal
pathways [24,44]. Hence, either toxic Aβ oligomers
cause degeneration of specific cortico-cortical path-
ways or degeneration of cortico-cortical pathways
results in the deposition of Aβ [13]. The objective of
this study was to determine whether the spatial
pattern of Aβ deposits in the cortex was influenced
by genetic factors. Hence, the spatial patterns of
diffuse, primitive, and classic Aβ deposits were stud-
i ed in three groups of AD cases: (1) early-onset
familial AD (EO-FAD) linked to mutations of APP or
PSEN1, (2) late-onset FAD (LO-FAD) not linked to
APP or PSEN genes, and (3) cases of SAD. In addi-
tion, the influence of APOE genotype on the spatial
patterns of Aβ deposits was studied.
Material and methods
Cases
Eighteen cases of AD (details in Table I), obtained
from the Brain Bank, Department of Neuropatholo-
gy, Institute of Psychiatry, King’s College, London,
UK, were studied. Informed consent was given for
the removal of all brain tissue according to the 1996
Declaration of Helsinki (as modified Edinburgh,
2000). Patients were clinically assessed and all ful-
filled the ‘National Institute of Neurological and
Com municative Disorders and Stroke and the
Alzheimer Disease and Related Disorders Associa-
tion’ (NINCDS/ADRDA) criteria for probable AD [52].
The histological diagnosis of AD was established by
the presence of widespread neocortical SP consis-
tent with the ‘Consortium to Establish a Registry of
Alzheimer Disease’ (CERAD) criteria [42] and ‘Natio -
nal Institute on Aging (NIA)-Reagan Institute’ criteria
[36,43]. The cases were divided into three groups: 
(1) EO-FAD (onset  ≤ 65 yrs) (N = 4); two cases linked
to the APP717 mutation and two to PSEN1 mutations
(G209V and E280A), (2) LO-FAD (≥ 65 yrs) (N = 5) not
associated with mutations of APP or PSEN genes,
and (3) SAD (N = 9) with no evidence of familial
involvement. The EO-FAD cases expressed APOE
genotype ε2/3 or ε3/3, while two of the LO-FAD cas-
es expressed APOE genotype ε3/4. Of the SAD cas-
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es, four expressed APOE genotype ε3/4, one case
ε4/4, and the remaining cases expressed genotype
ε2/3 or ε3/3. 
Tissue preparation
Blocks of the frontal and temporal cortex were
taken at the level of the genu of the corpus callosum
and lateral geniculate body respectively to study the
superior frontal gyrus (SFG), superior temporal gyrus
(STG) and the parahippocampal gyrus (PHG). Tissue
was fixed in 10% phosphate-buffered formal saline
and embedded in paraffin wax. 7 µm coronal sec-
tions were stained with a rabbit polyclonal antibody
(Gift of Prof. B.H. Anderton, Institute of Psychiatry,
King’s College London) raised to the 12-28 amino
acid sequence of the Aβ protein [50], and which 
distinguishes the major types of Aβ deposit [5]. 
The antibody was used at a dilution of 1 in 1200 and
the sections incubated at 4°C overnight. Sections
were pre-treated with 98% formic acid for 6 minutes,
which enhances Aβ immunoreactivity. Aβ was visua -
lised using the streptavidin-biotin horseradish per-
o xidase procedure with diaminobenzidine as the 
chromogen. Sections were also stained with hae ma-
toxylin. Aβ deposits were identified according to the
criteria of Delaere et al. [22]: (1) diffuse deposits
were 10-200 µm in diameter, lightly stained, irregu-
lar in shape, and with diffuse boundaries; (2) primi-
tive deposits were 20-60 µm, well demarcated, sym-
metrical in shape, and strongly stained; and (3) clas sic
deposits were 20-100 µm and had a distinct central
amyloid core surrounded by a ‘corona’ of DN. 
Case Sex Age Onset Group Genetic APOE genotype
linkage
A M 65 NA EO-FAD APP717 3/3
B F 59 NA EO-FAD APP717 3/3
C F 61 NA EO-FAD PSEN1 3/3
D F 45 40 EO-FAD PSEN1 2/3
E F 72 66 LO-FAD ND 2/3
F F 86 80 LO-FAD ND 3/4
G F 77 72 LO-FAD ND 3/3
H F 79 68 LO-FAD ND 3/4
I F 85 76 LO-FAD ND 3/3
J M 80 77 SAD – 3/3
K F 87 82 SAD – 3/4
L F 64 59 SAD – 4/4
M F 91 83 SAD – 3/4
N M 73 66 SAD – 2/3
O F 82 75 SAD – ND
P F 91 85 SAD – 3/4
Q F 86 83 SAD – 3/4
R F 90 NA SAD – ND
Table I. Demographic and genetic data of the Alzheimer’s disease (AD) cases studied 
APOE – apolipoprotein E, APP – amyloid precursor protein, EO-FAD – early-onset familial Alzheimer’s disease, LO-FAD – late-onset familial Alzheimer’s disease,
SAD – sporadic Alzheimer’s disease, PSEN1 – presenilin 1, M – male, F – female, ND – not determined, NA – data not available
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Morphometric methods
The spatial patterns of the Aβ deposits were
studied parallel to the pia mater in the upper 1 mm
of the cortex using a magnification of × 100 [13].
A strip of cortex 17 600 to 25 600 µm in length, and
which included a sulcus and a gyrus, was studied
using 1000 × 200 µm contiguous sample fields, 
the short dimension of the field being aligned with
the surface of the pia mater [7]. Hence, the sample
field included laminae I, II, and III. Between 64 and
128 contiguous sample fields were used to sample
each gyrus. A micrometer grid with grid lines at
intervals of 10 µm was used as the sample field. 
The number of diffuse, primitive, and classic Aβ
deposits was counted in each field.
Data analysis
The data were analysed by spatial pattern analy-
sis [2,10,13,14]. Essentially, the variance/mean (V/M)
ratio of the data measures the degree of non-ran-
domness present and determines whether Aβ de -
posits were distributed randomly (V/M = 1), regular-
ly (V/M < 1), or in clusters (V/M > 1) along the strip
of cortex parallel to the pia mater. The V/M ratio was
calculated at increasing field sizes by adding togeth-
er successively data from adjacent sample fields,
e.g., 200 × 1000 µm (the original field size) and then
at 400 × 1000 µm, 800 × 1000 µm, etc., up to a size
limited by the length of cortex sampled. The V/M
ratio was plotted against the increasing field size to
reveal the spatial pattern. If the deposits were clus-
tered, then the analysis indicated whether the clus-
ters themselves were randomly or regularly distri -
buted and provides an estimate of the mean
dimension of the clusters in a plane parallel to the
pia mater. 
The frequencies of the different types of spatial
pattern (random, regular, regularly distributed clus-
ters, large-scale clustering) were compared between
groups using chi-square (χ2) contingency table tests.
In addition, size of the clusters, measured parallel to
the pia mater and averaged over all gyri, was com-
pared between groups using two-factor analysis of
variance (ANOVA) (STATISTICA software, StatSoft
Inc., 2300 East 14th St, Tulsa, OK 74104, USA).
Results
The spatial patterns of the diffuse, primitive, 
and classic Aβ deposits in the PHG of a single case
(Case C, EO-FAD, PSEN1 mutation) are shown in 
Fig. 1. The V/M ratio of the diffuse deposits increased
with field size without reaching a significant peak
consistent with the presence of a large cluster of dif-
fuse Aβ deposits. The V/M ratio of the primitive
deposits exhibited a significant peak at a field size of
200 µm, suggesting the presence of clusters of pri -
mitive deposits, 200 µm in diameter, regularly dis-
tributed parallel to the pia mater. The V/M ratio of
the classic deposits was significantly less than unity
at all field sizes, suggesting a regular or uniform dis-
tribution of deposits.
The frequency of the different types of spatial
patterns exhibited by the diffuse, primitive, and
classic deposits in EO-FAD, LO-FAD, and SAD is
shown in Table II. The diffuse deposits were distri -
buted either in clusters which were regularly distri -
buted parallel to the pia mater or in large clusters,
no significant differences in spatial pattern being
observed between groups. The primitive Aβ de -
posits, however, were more frequently distributed 
in regularly distributed clusters parallel to the pia
mater in EO-FAD and LO-FAD and were more fre-
quently distributed in large clusters in SAD (χ2 = 3.94,
P < 0.05). In addition, the classic Aβ deposits were
less frequently distributed in regular clusters and
more frequently distributed in large clusters in 
EO-FAD compared with LO-FAD (χ2 = 6.45, P < 0.05).




















Fig. 1. The spatial patterns of the diffuse, primi-
tive, and classic Aβ deposits in the PHG of a sin-
gle case (Case C, PSEN1).
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classic deposits, averaged over cortical regions, are
shown in Fig. 2. The mean size of the diffuse deposits
differed between groups (F = 3.64, P < 0.05), cluster
size being significantly less in SAD compared with
EO-FAD and LO-FAD. There were no significant diffe -
rences in the cluster sizes of the primitive (F = 1.89,
P > 0.05) or classic deposits (F = 0.66, P > 0.05)
between groups. Within the EO-FAD group, there
were no differences in the spatial pattern of the Aβ
deposits between APP and PSEN1 cases.
A comparison of the spatial patterns exhibited
by the Aβ deposits in cases classified according to
APOE genotype is shown in Table III. There were no
significant differences in the spatial patterns of the
diffuse (χ2 = 0.02, P < 0.05), primitive (χ2 = 0.09, 
P < 0.05), or classic (χ2 = 6.16, P < 0.05) Aβ deposits
in cases expressing APOE genotypes ε2/3 and ε3/3,
compared with those expressing genotypes ε3/4
and ε4/4. The mean cluster sizes of the diffuse,
primitive, and classic deposits, averaged over the
three cortical regions, are shown in Fig. 3. There were
no significant differences in the cluster sizes of the
diffuse (F = 0.27, P > 0.05) primitive (F = 2.45, 
P > 0.05) or classic deposits (F = 0.61, P > 0.05)
between cases expressing different APOE genoty -
pes, although there is some evidence that the clus-
ter size of the classic deposits may be greater in cas-
es expressing allele ε4.
Aβ in Alzheimer’s disease
Type of spatial pattern
Group Aβ R Reg Regular clusters Large clusters
(200-3200  µm) (≥  3200  µm)
EO-FAD Diffuse 2 0 6 3
Primitive 0 0 8 3
Classic 0 1 5 5
LO-FAD Diffuse 0 0 8 12
Primitive 0 0 18 5
Classic 2 1 11 1
SAD Diffuse 0 0 22 13
Primitive 0 0 17 18
Classic 0 3 13 3
Table II. Frequency of spatial patterns of β-amyloid (Aβ) deposits in early-onset familial Alzheimer’s disease
(EO-FAD), late-onset familial Alzheimer’s disease (LO-FAD), and sporadic Alzheimer’s disease (SAD). Data
are number of brain regions exhibiting a specific spatial pattern summed over three cortical regions 
R – random distribution, Reg – regular or uniform distribution
Comparison of frequencies: Chi-square (χ2) contingency tables: Diffuse deposits, LO-FAD vs. SAD χ2 = 1.83 (P > 0.05), LO-FAD vs. EO-FAD χ2 = 0.86 (P > 0.05),
EO-FAD vs. SAD χ2 = 0.03 (P > 0.05); Primitive deposits, LO-FAD vs. SAD χ2 = 3.94 (P < 0.05), LO-FAD vs. EO-FAD χ2 = 0.06 (P > 0.05), EO-FAD vs. SAD 
























Fig. 2. The mean cluster sizes of the diffuse, pri -
mitive, and classic deposits in early-onset familial
Alzheimer’s disease (EO-FAD), late-onset familial
AD (LO-FAD) and sporadic AD (SAD). ANOVA 
Two-factor: patient group F = 0.11 (P > 0.05), Aβ
deposit F = 1.92 (P > 0.05), Interaction F = 2.00 
(P > 0.05); one-way for each deposit type: Diffuse
F = 3.64  (P < 0.05), Primitive F = 1.89 (P > 0.05);
Classic F = 0.66 (P > 0.05).
Diffuse Primitive Classic
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Discussion
The Aβ deposits exhibited two common spatial
patterns: (1) deposits were clustered with cluster
sizes in the size range 200-3200 µm in diameter, the
clusters being regularly distributed parallel to the pia
mater; and (2) deposits were clustered on a larger
scale, usually greater than 3200 µm in diameter,
without regular spacing. These results are similar to
those previously reported for Aβ deposits [13,15,17]
and for NFT [3,11] in AD. 
Regular clustering of the diffuse and primitive
deposits could be a consequence of degeneration of
the cortico-cortical connections [15,24]. In the cere-
bral cortex, the cells of origin of the cortico-cortical
projections are clustered and occur in bands which
are regularly distributed along the cortex parallel to
the pia mater. Individual bands of cells vary in width
approximately from 400 to 1000 µm depending on
cortical area [33]. In some gyri, the estimated widths
of the clusters of diffuse and primitive Aβ deposits
suggest an association with these projections [44].
By contrast, classic deposits often cluster around
cerebral blood vessels, especially the vertically pene-
trating arterioles, which also exhibit a regular pat-
tern of distribution parallel to the pia mater in lami-
nae II/III [9]. By contrast, the large-scale clustering of
deposits may be attributable to the aggregation of
amyloid within cortical sulci [13]. The density of both
neurons and blood vessels is greater in sulci com-
pared with the gyral crest, which could explain these
accumulations [4,26]. 
There were no significant differences in the 
frequency of the different types of spatial pattern 
of the diffuse deposits either between EO-FAD, 
LO-FAD, and SAD, or between cases classified
according to APOE genotype. Diffuse deposit clus-
ters, however, were larger in EO-FAD and LO-FAD
than in SAD, suggesting that initial deposition of Aβ
is greater in FAD and that a higher proportion of dif-
fuse deposits may be converted to primitive
deposits in SAD [5]. 
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Fig. 3. The mean cluster sizes of the diffuse,
primitive, and classic deposits in Alzheimer’s
disease cases classified according to apo lipo -
protein (APOE) genotype. ANOVA Two-factor:
patient group F = 0.27 (P > 0.05), Aβ deposit 






















2/3;3/3                                   3/4;4/4
Type of spatial pattern
APOE Aβ deposit R Reg Regular clusters Large clusters
genotype subtype (200-3200 µm) ( ≥ 6400 µm)
ε2/3,  ε3/3 Diffuse 0 0 9 6
Primitive 0 0 10 6
Classic 0 4 7 2
ε3/4,  ε4/4 Diffuse 0 0 12 6
Primitive 0 0 13 8
Classic 2 0 7 3
Table III. Frequency of spatial patterns of Aβ deposits in early-onset familial Alzheimer’s disease (EO-FAD),
late-onset familial Alzheimer’s disease (LO-FAD), and sporadic Alzheimer’s disease (SAD) classified accord-
ing to apolipoprotein (APOE) genotype 
R – random, Reg – regular
Chi-square (χ2) contingency tables: Diffuse χ2 = 0.02 (P > 0.05), Primitive χ2 = 0.09 (P > 0.05), Classic χ2 = 6.16 (P > 0.05)
Diffuse Primitive Classic
Apolipoprotein genotype
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Clusters of primitive deposits were more fre-
quently regularly distributed in EO-FAD and LO-FAD
and more frequently present in non-regularly dis-
tributed clusters in SAD. Hence, in FAD, conversion of
diffuse to primitive deposits may result in a more
localized and specific spatial pattern of deposits in
relation to the cortico-cortical pathways. By contrast,
in SAD, a greater proportion of diffuse deposits may
be converted to primitive deposits, resulting in clus-
ters of primitive deposits of similar size to those of
FAD and clusters of diffuse deposits smaller than
those of FAD.
Classic deposits were less frequently distributed
in regular clusters and more frequently present in
larger clusters in EO-FAD. Previous studies suggest
that classic deposits are more likely to be clustered
around blood vessels in SAD than in FAD [12]. Classic
deposits also occur with greater density in AD cases
with extensive capillary amyloid angiopathy (CAA)
[16]. CAA is more frequent in cases with specific
gene mutations, APP692 mutations, for example, re -
sulting in extensive CAA and numerous large-cored
deposits clearly distinct in morphology from those of
SAD [21,46]. Hence, in cases with APP and PSEN
mutations, the blood-brain barrier may be signifi-
cantly damaged, increasing diffusion from blood
ves sels, and influencing the formation of classic de -
posits at greater distances from blood vessels than
in LO-FAD and SAD.
All types of Aβ deposit exhibited similar spatial
patterns and cluster sizes in cases classified accord-
ing to APOE genotype. APOE genotype has been
identified as a major risk factor in AD, individuals
with the disease having 2-3 times the frequency of
allele ε4 compared with non-demented elderly con-
trols [51]. The presence of allele ε4 may accelerate
the development of AD pathology within the aged
brain, and hence is often associated with an earlier
disease onset [29]. In addition, the majority of stud-
ies report increased amyloid deposition in individu-
als expressing allele ε4 [18,19,25]. The present data
suggest, however, that APOE genotype had little
effect on the spatial pattern of the Aβ deposits in
the frontal and temporal lobe. Some studies suggest
that Aβ deposition, specifically in the form of Aβ40,
may be more closely related to APOE genotype
[35,39]. Hence, it would be of interest to study the
spatial patterns of Aβ40 and Aβ42 deposits separate-
ly in relation to APOE genotype. 
In conclusion, the data suggest that gene expres-
sion had relatively little effect on the type of spatial
pattern exhibited by the diffuse Aβ deposits. The
aver age cluster size of the diffuse deposit, however,
was larger in FAD compared with SAD, suggesting
greater initial Aβ deposition in FAD. However, cluster
sizes of the primitive deposits were similar in FAD
and SAD, suggesting that (1) a higher proportion of
diffuse deposits may be converted to primitive
deposits in SAD, and (2) primitive deposits may be
more closely related to specific cortico-cortical path-
ways in FAD. Classic deposits were more extensively
distributed in the cortex in FAD than SAD. The pres-
ence of the APOE allele ε4 had little effect on the
spatial patterns or cluster sizes of Aβ deposits. 
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